Predictive Oncology Inc. (NASDAQ:POAI) said it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases, to pursue a novel method to enhance Integra’s ability to use gene editing for future cancer therapies.
“Our novel formulation technology and protein expression experience positions Predictive Oncology to help advance Integra’s goals,” said Larry DeLucas, Senior Vice President of Biologics at Predictive Oncology.
Predictive Oncology said it was chosen by Integra because of the company’s protein expression experience and unique ability to optimize solubility and physical stability for expressed proteins.
Predictive Oncology uses a proprietary automated technology, called high-throughput self-interaction chromatography to rapidly and accurately measure biomolecular interactions that assist pharmaceutical and biotech companies in drug development, the company noted.
Integra Therapeutics CEO Avencia Sanchez-Mejias said this collaboration could set the stage for new discoveries in cell therapy.
“We are excited about the potential that Predictive Oncology offers in advancing our goals in advanced therapies,” Sanchez-Mejias said.
The company noted that the news comes on the heels of Predictive Oncology’s release of a novel product designed for endotoxin removal and which involves a new high-capacity endotoxin column called EndoBind-R II.
This highly specialized process and unique product design continually demonstrates superior performance and consistently delivers conclusive results, Predictive Oncology said.
Predictive Oncology is a science-driven company on the leading edge of oncology drug discovery, offering an unrivalled suite of solutions for the biopharma industry.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie